Literature DB >> 2414233

Multiple epitopes on a human breast-carcinoma-associated antigen.

M R Price, S Edwards, A Owainati, J E Bullock, B Ferry, R A Robins, R W Baldwin.   

Abstract

The monoclonal antibody (MAb) NCRC-11 identifies an epitope expressed variably in human breast cancer. The degree of expression of this epitope in primary operable tumours is closely related to the subsequent clinical course of the disease (Ellis et al., 1985). The target antigen for NCRC-11 was isolated from subcellular membranes of breast carcinomas and purified by immunoadsorbent chromatography. NCRC-11 epitopes were expressed upon a large glycoprotein of more than 400 kd. This material was susceptible to degradation by pronase and papain and contained N-acetylglucosamine, as indicated by its binding to wheat-germ agglutinin. The NCRC-11-defined antigen expressed epitopes for the anti-human milk-fat globule membrane antibodies HMFG-1 and HMFG-2, and other antibodies against epithelial membrane antigens (EMA, LICR-LON-M8). The reactivity of these antibodies with tumour membranes was also similar, but not identical, to that of the NCRC-11 antibody. In competitive binding-inhibition assays, these antibodies partially inhibited the binding of 125I-NCRC-11 antibody to antigen, suggesting that the epitopes involved are topographically closely associated. Sandwich immunoassays demonstrated that NCRC-11 epitopes are likely to represent repeated structures of the NCRC-11 antigen. The findings presented are interpreted as indicating that the NCRC-11 antigen expresses a variety of epitopes which are associated with normal differentiation and malignant change.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2414233     DOI: 10.1002/ijc.2910360509

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma.

Authors:  M V Croce; M E Rabassa; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Detection and isolation of MUC1 mucin from larynx squamous cell carcinoma.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Application of a subcellular membrane-antibody binding assay for the analysis of antigen expression in human tumours.

Authors:  M R Price; S Edwards; R W Baldwin
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  Association of a alpha1 acidic glycoprotein and squamous cell carcinoma of the head and neck.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

5.  Analysis of the tumour-associated antigen TAG-12 by monoclonal antibody 7A9 in normal, benign and malignant mammary tissues.

Authors:  M Werner; R von Wasielewski; J Bernhards; A Georgii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

6.  Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11.

Authors:  M R Price; A J Clarke; J F Robertson; C O'Sullivan; R W Baldwin; R W Blamey
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  The expression of human FUT1 in HT-29/M3 colon cancer cells instructs the glycosylation of MUC1 and MUC5AC apomucins.

Authors:  Anna López-Ferrer; Carme de Bolós
Journal:  Glycoconj J       Date:  2002-01       Impact factor: 2.916

8.  Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

9.  Apical MUC1 expression revealed on the foveolar epithelium in H. pylori gastritis.

Authors:  M Rashid; A S Teixeira; U Qureshi; S P Pereira; M R Novelli; D M Swallow
Journal:  Br J Cancer       Date:  2013-02-14       Impact factor: 7.640

10.  Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3.

Authors:  A R Dixon; M R Price; C W Hand; P E Sibley; C Selby; R W Blamey
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.